© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.